Madhusudhan Gowravaram

Author

AstraZeneca (United States)

Also Known As

Gowravaram, Madhusudhan, M. Gowravaram, Madhusudhan Gowravaram, Madhusudhan R. Gowravaram

Publications

563

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)South College

About

Madhusudhan Gowravaram is an author at AstraZeneca (United States) specializing in drug discovery, medicine, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	345
2	Natural Sciences	7	7	298
3	Biochemistry	6	6	243
4	Engineering	1	1	68
5	Biomolecular Engineering	1	1	68

Madhusudhan Gowravaram

Publications

552

Citations

H-Index

Page 1

	Year	Citations
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases Gregory S. Basarab, Günther Kern, John McNulty, Scientific Reports	2015	100
“Traceless” solid-phase synthesis of furans via 1,3-dipolar cycloaddition reactions of isomünchnones Madhusudhan Gowravaram, Mark A. Gallop Tetrahedron Letters EngineeringOrganic ChemistryChemistry1,3-Dipolar Cycloaddition ReactionsSynthesis Method	1997	68
Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914) Gregory S. Basarab, P. Doig, Vincent Galullo, Journal of Medicinal Chemistry Bioorganic ChemistryMolecular BiologyClinical CandidatePharmacotherapyPharmaceutical Chemistry	2015	68
Inhibition of Matrix Metalloproteinases by Hydroxamates Containing Heteroatom-Based Modifications of the P1' Group Madhusudhan Gowravaram, Jeffrey S. Johnson, Daniel Delecki, Journal of Medicinal Chemistry Pharmaceutical ScienceDual Hfs/hnc InhibitorChemical BiologyEnzymatic ModificationPharmaceutical Chemistry	1995	58
Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization Gregory S. Basarab, Patrick Brassil, P. Doig, Journal of Medicinal Chemistry Pharmaceutical ScienceDrug TargetStaphylococcus AureusMolecular BiologyChemical Biology	2014	55
Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): Pyridodiazepine amines Bolin Geng, Gregory S. Basarab, Janelle Comita-Prevoir, Bioorganic & Medicinal Chemistry Letters MedicineGlutamate RacemaseMechanism Of ActionPharmacological AgentSelective Inhibitors	2008	49
Determination of Pharmacophoric Geometry for Collagenase Inhibitors Using a Novel Computational Method and Its Verification Using Molecular Dynamics, NMR, and X-ray Crystallography Arup K. Ghose, Margaret E. Logan, Adi M. Treasurywala, Journal of the American Chemical Society X-ray CrystallographyPharmaceutical ScienceBiomolecular Structure PredictionCollagenase InhibitorsPharmacophoric Geometry	1995	42
Discovery of bacterial NAD+-dependent DNA ligase inhibitors: Optimization of antibacterial activity S. Stokes, Hoan K. Huynh, Madhusudhan Gowravaram, Bioorganic & Medicinal Chemistry Letters BiochemistryNatural SciencesAntibacterial ActivityOligonucleotideAntibacterial Agent	2011	33
Discovery of bacterial NAD+-dependent DNA ligase inhibitors: Improvements in clearance of adenosine series S. Stokes, Madhusudhan Gowravaram, Hoan K. Huynh, Bioorganic & Medicinal Chemistry Letters Cellular EnzymologyAdenosine SeriesBiochemistryNatural SciencesOligonucleotide	2011	22
Hydroxamate inhibitors of human gelatinase B (92 kDa) Robert C. Wahl, Tricia A. Pulvino, Alan M. Mathiowetz, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryMedicineHydroxamate InhibitorsPharmacotherapyAnti-cancer Agent	1995	20

Page 1